Amg Funds Has Boosted Qualcomm (QCOM) Holding; Aclaris Therapeutics (ACRS) Sellers Decreased By 4.86% Their Shorts

May 23, 2018 - By Hazel Jackson

QUALCOMM Incorporated (NASDAQ:QCOM) Logo

Amg Funds Llc increased Qualcomm Inc (QCOM) stake by 69% reported in 2017Q4 SEC filing. Amg Funds Llc acquired 10,316 shares as Qualcomm Inc (QCOM)’s stock declined 15.28%. The Amg Funds Llc holds 25,267 shares with $1.62 million value, up from 14,951 last quarter. Qualcomm Inc now has $85.87 billion valuation. The stock increased 0.92% or $0.53 during the last trading session, reaching $57.92. About 4.38 million shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 3.21% since May 23, 2017 and is downtrending. It has underperformed by 14.76% the S&P500.

Aclaris Therapeutics Inc (NASDAQ:ACRS) had a decrease of 4.86% in short interest. ACRS’s SI was 5.01 million shares in May as released by FINRA. Its down 4.86% from 5.27M shares previously. With 290,300 avg volume, 17 days are for Aclaris Therapeutics Inc (NASDAQ:ACRS)’s short sellers to cover ACRS’s short positions. The SI to Aclaris Therapeutics Inc’s float is 19.8%. The stock increased 1.53% or $0.29 during the last trading session, reaching $19.28. About 72,815 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 45.27% since May 23, 2017 and is downtrending. It has underperformed by 56.82% the S&P500.

Since January 9, 2018, it had 0 insider purchases, and 8 insider sales for $7.62 million activity. Another trade for 663 shares valued at $37,519 was sold by ROGERS ALEXANDER H. On Friday, March 9 the insider THOMPSON JAMES H sold $3.14 million. Another trade for 16,082 shares valued at $852,989 was made by AMON CRISTIANO R on Tuesday, May 8. Rosenberg Donald J sold $618,603 worth of stock or 11,670 shares. Another trade for 43,000 shares valued at $2.81 million was made by GROB MATTHEW S on Tuesday, January 9.

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.02, from 0.85 in 2017Q3. It worsened, as 89 investors sold QCOM shares while 518 reduced holdings. 160 funds opened positions while 346 raised stakes. 1.11 billion shares or 0.73% more from 1.10 billion shares in 2017Q3 were reported. Trilogy Lp holds 6.09% or 1.50 million shares in its portfolio. Hbk Investments Limited Partnership reported 1.8% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Alpine Associates Mgmt holds 581,443 shares or 1.33% of its portfolio. Quantitative Invest Ltd invested in 0.24% or 258,200 shares. Tci Wealth Advsr stated it has 7,805 shares or 0.22% of all its holdings. Kcm Advsrs Ltd Liability reported 6,312 shares. Sumitomo Mitsui Asset holds 0.13% in QUALCOMM Incorporated (NASDAQ:QCOM) or 131,772 shares. Bremer Tru National Association reported 0.06% in QUALCOMM Incorporated (NASDAQ:QCOM). Delta Cap Lc reported 30,735 shares. Perkins Coie Trust Communication reported 1.12% stake. Checchi Capital Advisers Ltd Co has 0.25% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 28,802 shares. Mark Sheptoff Planning Limited Liability Company owns 250 shares. Miller Howard Invs Ny reported 1.08M shares. 39,057 were accumulated by Private Advisor Grp Ltd Com. Rand Wealth Limited Liability accumulated 0.05% or 6,718 shares.

Amg Funds Llc decreased Iron Mtn Inc New (NYSE:IRM) stake by 15,524 shares to 71,187 valued at $2.69M in 2017Q4. It also reduced Teradata Corp Del (NYSE:TDC) stake by 10,019 shares and now owns 62,986 shares. Valero Energy Corp New (NYSE:VLO) was reduced too.

Among 37 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 15 have Buy rating, 2 Sell and 20 Hold. Therefore 41% are positive. Qualcomm Inc. had 157 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Buy” rating by RBC Capital Markets on Monday, April 23. Canaccord Genuity maintained the shares of QCOM in report on Tuesday, January 16 with “Buy” rating. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) has “Overweight” rating given on Monday, May 22 by JP Morgan. KeyBanc Capital Markets maintained it with “Overweight” rating and $73 target in Thursday, February 1 report. As per Wednesday, November 1, the company rating was maintained by Canaccord Genuity. As per Friday, May 26, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, October 12. As per Friday, November 3, the company rating was maintained by Citigroup. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) earned “Buy” rating by RBC Capital Markets on Monday, January 29. As per Wednesday, May 16, the company rating was maintained by Canaccord Genuity.

More notable recent QUALCOMM Incorporated (NASDAQ:QCOM) news were published by: Fool.com which released: “Samsung Is Making Its Move Against Qualcomm” on May 21, 2018, also Nasdaq.com with their article: “China Eases the Pressure on Qualcomm’s NXP Deal” published on May 15, 2018, Seekingalpha.com published: “Beijing Approves Microchip Deal, Boding Well For Qualcomm-NXP” on May 17, 2018. More interesting news about QUALCOMM Incorporated (NASDAQ:QCOM) were released by: Investorplace.com and their article: “President Trump Unexpectedly Made Tech Stocks Great Again” published on May 23, 2018 as well as Nasdaq.com‘s news article titled: “Facebook, Qualcomm Teaming Up on High-Speed Internet” with publication date: May 21, 2018.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. As per Friday, June 10, the company rating was initiated by Guggenheim. Leerink Swann initiated Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rating on Tuesday, November 29. Leerink Swann has “Outperform” rating and $54 target. The firm earned “Buy” rating on Monday, November 2 by Citigroup. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Monday, September 19. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Friday, July 28. The firm has “Market Perform” rating given on Friday, September 30 by JMP Securities. Cantor Fitzgerald maintained the shares of ACRS in report on Tuesday, November 7 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Thursday, August 31. Jefferies maintained Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rating on Monday, June 26. Jefferies has “Buy” rating and $3600 target. The stock has “Outperform” rating by William Blair on Monday, November 2.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $595.87 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

More notable recent Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news were published by: Globenewswire.com which released: “Aclaris Therapeutics to Attend Upcoming Investor Conferences” on May 10, 2018, also Seekingalpha.com with their article: “Aclaris Therapeutics’ (ACRS) CEO Neal Walker on Q1 2018 Results – Earnings Call Transcript” published on May 13, 2018, Nasdaq.com published: “Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting” on May 16, 2018. More interesting news about Aclaris Therapeutics, Inc. (NASDAQ:ACRS) were released by: Benzinga.com and their article: “Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching” published on May 19, 2018 as well as Nasdaq.com‘s news article titled: “Aclaris Therapeutics Announces Availability of ESKATAâ„¢ (Hydrogen Peroxide) Topical Solution, 40% (w/w)” with publication date: May 07, 2018.

QUALCOMM Incorporated (NASDAQ:QCOM) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>